

JAKAVI - Home - HCP

[Prescribing information](#)

Image



Image



## **JAKAVI® (ruxolitinib)**

JAKAVI® (ruxolitinib) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. JAKAVI® is also indicated for adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.<sup>1</sup>



---

**JAKAVI® (ruxolitinib) in myelofibrosis**

**JAKAVI® (ruxolitinib) in myelofibrosis**

See more details

Hide details





---

**JAKAVI® (ruxolitinib) in polycythaemia vera**

**JAKAVI® (ruxolitinib) in polycythaemia vera**

See more details



Hide details

## Reference

1. JAKAVI® (ruxolitinib) Summary of Product Characteristics.

UK | November 2024 | FA-11208694

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report), or alternatively email [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com) or call 01276 698370.

---

**Source URL:** <https://prod.pro.novartis.com/uk-en/medicines/haematology/jakavi>